Several clinical studies have assessed the potential value of LCN2 as a biomarker for neurodegenerations including vascular dementia [32], mild cognitive impairment [33] or preclinical stage of Alzheimer’s disease [34]. Here, LCN2 is linked to early-onset autosomal dominant Alzheimer disease.